Conventional-Dose versus High-Dose Chemotherapy for Relapsed Germ Cell Tumors

Table 1

Prospective studies examining the use of initial salvage conventional-dose chemotherapy.

Author (year)	N	CDCT Regimen(s)	Notable inclusion or exclusion criteria	EP/BEP as first-line therapy	CR/PR to first-line therapy	IR to first-line therapy	CR	Median f/u (months)	Durable remission
McCaffrey et al. [4]	56	VeIP or VIP	None	53%	36%	64%	36%	52	23%
Loehrerr et al. [5]	135	VeIP	Cisplatin-refractory patients excluded^a	100%	100%	0%	50%	72^b	24%
Kondagunta et al. [14]	46	TIP	Included only patients with CR- or PR-negative marker to first line, gonadal primary, and <6 cycles of cisplatin in first line	74%	100%	0%	70%	69	63%
Fizazi et al. [17]	37	GIP	Included only patients with CR or PR-negative marker to first line, gonadal primary, and <6 cycles of cisplatin in first line	86%	100%	0%	54%	53	51%

CDCT, conventional-dose chemotherapy; EP, etoposide plus cisplatin; BEP; bleomycin, etoposide, and cisplatin; IR; incomplete response; CR, complete response; f/u, follow-up; VIP, etoposide, ifosfamide, and cisplatin; VeIP, vinblastine, ifosfamide, and cisplatin; GIP, gemcitabine, ifosfamide, and cisplatin; ^aprogression at <3 weeks after completion of first-line chemotherapy; ^bminimal (not median) follow-up.